GFM FTA LLC – Trademark Portfolio

Entity Type: 16

GFM FTA LLC holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 3 are pending. Notable registered marks include BUCODINE, MIGRAFEIN, BUSCOLICOS, and BUSCOMPOSITUM. The owner is based in SHERIDAN, WY.

1309 COFFEEN AVE SUITE 13815

SHERIDAN, WY 82801

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

GFM FTA LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does GFM FTA LLC have?

GFM FTA LLC has 8 U.S. trademarks filed with the USPTO. Of these, 4 registered, 3 pending, 1 cancelled.

What trademark classes does GFM FTA LLC file in?

GFM FTA LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are GFM FTA LLC's most well-known trademarks?

GFM FTA LLC's registered trademark portfolio includes well-known marks such as BUCODINE, MIGRAFEIN, BUSCOLICOS, and BUSCOMPOSITUM. These are among 4 currently registered trademarks in the portfolio.

What is GFM FTA LLC's trademark registration success rate?

GFM FTA LLC has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 3 applications are pending review.